Antithrombotic therapy for long-term secondary prevention of acute coronary syndrome in high-risk patients

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Acute coronary syndrome (ACS) poses a significant clinical challenge due to high rates of recurrent ischemic events.
• Current acute management involves parenteral anticoagulants and dual-antiplatelet therapy, with dual-antiplatelet therapy also recommended for long-term secondary prevention.
• Despite advancements, ACS patients have a substantial risk (around 10%) of experiencing another event within 12-15 months.

Purpose of the Study:

• To review the current standard of care for long-term secondary antithrombotic strategies in ACS patients.
• To identify high-risk patient populations for recurrent ACS events using registry data.
• To summarize recent Phase III trial data on antiplatelet and anticoagulant therapies to inform treatment strategies.

Main Methods:

• Review of current standard of care for ACS management.
• Analysis of data from GRACE and CRUSADE registries to identify high-risk patient groups.
• Summary of recent Phase III clinical trial data for antiplatelet and anticoagulant agents.

Main Results:

• Certain patient groups, including the elderly and those with renal impairment or heart failure, are at higher risk for recurrent ACS.
• Evidence suggests underuse of guideline-recommended therapies in these high-risk ACS populations.
• Phase III trials provide insights into differential benefits of specific long-term antithrombotic strategies across patient subgroups.

Conclusions:

• Optimizing long-term secondary prevention strategies is crucial for improving prognosis in ACS patients.
• Targeted application of evidence-based antithrombotic therapies in high-risk populations is needed.
• Improved implementation of guideline recommendations can enhance patient outcomes after an ACS event.